prime DX

prime DX is the evolved analysis of 1021 genes and immunotherapy biomarkers HLA, MSI, TMB and PD-L1 as well as the LOH biomarker for PARP inhibitors therapy and is designed to provide the physician with clear insight into treatment options, such as:

  • Targeted therapy
  • Immunotherapy
  • Chemotherapy

Now, the analysis of the molecular profile of the tumor is also carried out in a Liquid Biopsy with the New prime DX Liquid test!

Order the test

Ask your physician if you are eligible for the prime DX test.

Sample requirement

Tissue from surgery or biopsy which is embedded in paraffin (FFPET) or liquid biopsy (Plasma) is required for this test. Your sample will be collected per your physician’s' instructions.

Analysis Process

Your sample will arrive to our accredited laboratory and your report will be generated and released to you and your physician in 15 working days.


Your report will be electronically released to your physician via email and/or uploaded to our secure portal, and to you via email or mail.

prime DX - molecular test

This breakthrough technology along with cloud computing and bioinformatics work together in order to analyze massive volumes of data from the patients’ genome and transform it into an interactive report providing information on these main categories of results:

  • Molecular profiling of the tumor tissue with details on specific gene mutations.
  • Suggested on-label Therapies that can be of great benefit to the specific patient with interactive feed of medical information
  • Suggested off-label therapies that can be of great benefit to the specific patient with interactive feed of medical information
  • Suggested investigational therapies with interactive feed of clinical trials .
  • Treatments with associated resistance- that will not be of benefit to the specific patient.
  • Medication suggestions with recorded indications.

prime DX Liquid


The new prime DX Liquid test includes a panel of 1021 genes and analyzes the immunotherapy biomarkers HLA, MSI and TMB. Additionally, it includes Loss of Heterozygosity (LOH) analysis, which can be used as a biomarker for PARP inhibitors therapy. This allows the physician to plan an effective treatment for the patient such as:

• Immunotherapy
• Chemotherapy
• PARP inhibitors
• Eligibility to participate in clinical studies

In addition, prime DX Liquid analyzes genes associated with genetic predisposition to cancer, providing the physician with information about the likelihood of a hereditary cancer syndrome.

Why choose prime DX?

  • prime DX analyzes 1021 genes associated with cancer syndromes and additionally the immunotherapy biomarkers HLA, MSI, PD-L1, TMB and LOH, giving the physician a clear picture of which treatments will benefit the patient and which will not, including immunotherapy, chemotherapy and of PARP inhibitors
  • Continuous support to the doctor and the patient from our experienced team
  • The report incorporates interactive links, which redirect the physician to medical information about the specific gene mutation and other relevant medical data
  • Analyzing several genes simultaneously with the use of a small sample of tissue of tissue or liquid biopsy (Plasma) at a low cost
  • State of the art technology, which has demonstrated high reproducibility, sensitivity and specificity

Who should be tested?

prime DX Molecular Cancer Test

prime DX is designed in order to allow you and your physician to select which is the optimal targeted treatment based on your unique tumor biology.

This test is designed for the following cases:

  • Aggressive tumors with no standard treatment
  • When the initial treatment plan has been completed but more treatment options must be taken under consideration.
  • Second line treatment
  • Tumors with many available treatment options where the physician must clarify which one will be the most effective on a particular patient.
  • For a clear indication of the patient’s response for the physician to know if a treatment plan would be appropriate and/or in order to create the most effective treatment plan. 
  • Tumors of unknown primary tumor
  • Rare tumors.
  • Tumors without an established “gold standard” treatment

2020 Genekor Medical S.A.. All Rights Reserved.

Web Design